Neomycin inhibits inositol phosphate formation in human platelets stimulated by thrombin but not other agonists

FEBS Letters
W Siess, E G Lapetina

Abstract

Neomycin (0.1-1 mM) added to human platelet-rich plasma or washed platelets prelabeled with [3H]inositol inhibits aggregation, ATP secretion (ID50 0.2 mM) and formation of [3H]inositol mono-, bis- and trisphosphate (ID50 0.6-0.8 mM) in response to thrombin (0.25 U/ml). The production of inositol phosphates in response to other platelet agonists (vasopressin, platelet activating factor, prostaglandin endoperoxide analogs and collagen) is not inhibited by neomycin, even at a concentration of 2 mM. At this concentration neomycin reduces the secretion of ATP stimulated by these agents (by up to 50%). The results indicate that neomycin has multiple effects on platelets that are unrelated to a specific inhibition of inositol phospholipid degradation by phospholipase C. Low concentrations (0.1-1 mM) of neomycin might selectively inhibit the interaction of thrombin with the platelet surface, and high concentrations (greater than 2 mM) might unspecifically reduce platelet secretion in response to various platelet agonists.

References

Oct 1, 1977·Biochemical Pharmacology·A Schibeci, J Schacht
Sep 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·J VergaraM Delay
Feb 1, 1986·The Journal of Clinical Investigation·J TakamatsuH R Gralnick
Sep 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·S E Rittenhouse

❮ Previous
Next ❯

Citations

Dec 18, 2001·Cell Motility and the Cytoskeleton·B Safiejko-Mroczka, P B Bell
Jan 1, 1993·Cell Motility and the Cytoskeleton·K M HedbergM Lindroth
May 1, 1991·Archives of Biochemistry and Biophysics·R D Nolan, E G Lapetina
Aug 15, 1990·Hearing Research·S BartolamiM Récasens
Nov 20, 1989·European Journal of Biochemistry·E HerrmannK H Jakobs
Jan 1, 1988·Experimental Cell Research·I Lassing, U Lindberg
Nov 14, 1998·The American Journal of Physiology·W Abebe, S J Mustafa
Jul 31, 1998·Experimental Cell Research·B Safiejko-Mroczka, P B Bell
Apr 1, 1988·Biochemical Pharmacology·B P HughesG J Barritt
Feb 13, 1989·Biochimica Et Biophysica Acta·E GabevS McLaughlin
Apr 14, 1987·Biochemical and Biophysical Research Communications·O B TysnesH Holmsen
Feb 29, 1988·Biochemical and Biophysical Research Communications·C CernescuN Cajal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

Biochemical and Biophysical Research Communications
N LangelandH Holmsen
Biochemical and Biophysical Research Communications
S NakashimaY Nozawa
Diabetic Medicine : a Journal of the British Diabetic Association
H Ege
© 2021 Meta ULC. All rights reserved